Slides
Page 1
JENALI Denali Therapeutics Webinar to Present Interim Data from DNL310 Phase 1/2 Hunter Syndrome Patient Study Ryan Watts , PhD , CEO Carole Ho , MD , CMO and Head of Development July 25 , 2021
Loading workspace
JENALI Denali Therapeutics Webinar to Present Interim Data from DNL310 Phase 1/2 Hunter Syndrome Patient Study Ryan Watts , PhD , CEO Carole Ho , MD , CMO and Head of Development July 25 , 2021
Your watchlist and earnings event details are available after you sign in.